Ciclosporin - Novartis

Drug Profile

Ciclosporin - Novartis

Alternative Names: Ciclosporin microemulsion - Novartis; Cyclosporin A microemulsion - Novartis; Cyclosporin microemulsion - Novartis; Cyclosporin modified - Novartis; Cyclosporine microemulsion - Novartis; Neoral; OLO400; Sandimmun Neoral; Sandimmune Neoral

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Erasmus MC; Novartis
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Atopic dermatitis; Heart transplant rejection; Liver transplant rejection; Myasthenia gravis; Pancreas transplant rejection; Psoriasis; Renal transplant rejection; Rheumatoid arthritis; Transplant rejection
  • Discontinued Ulcerative colitis

Most Recent Events

  • 12 Jul 2016 No development reported - Phase-I for Psoriasis in Netherlands (Topical)
  • 30 Jul 2014 Discontinued - Phase-II for Ulcerative colitis in England (PO)
  • 30 Sep 2007 Preregistration for Atopic dermatitis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top